A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

SCHOTT Pharma has announced an investment of €100m ($114m) to expand its manufacturing capacity for sterile RTU cartridges.

The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101.

Juvenescence has acquired Ro5 to enhance its AI/machine learning capabilities and improve research and development.